- The first interim efficacy analysis of the large-scale Phase 2/3 clinical trial evaluating Pfizer (NYSE:PFE) and BioNTech's (NASDAQ:BNTX) COVID-19 vaccine candidate, BNT162b2, showed it to be more than 90% effective seven days after the second dose in preventing infection in participants with no evidence of prior SARS-CoV-2 infection.
- 94 confirmed cases of COVID-19 were evaluated.
- The companies plan to review the results with global regulatory authorities.
- No safety signals were observed.
- The study will continue through the final analysis of 164 confirmed cases.
- An emergency use authorization (EUA) application will be made after the required safety milestone is achieved, expected to occur in the third week of November.
- COVID-19 vaccine-related tickers: Moderna (NASDAQ:MRNA) (+6%), Johnson & Johnson (NYSE:JNJ) (+4%), Merck (NYSE:MRK) (+1%), Sanofi (NASDAQ:SNY) (+2%), GlaxoSmithKline (NYSE:GSK) (+3%), Dynavax (NASDAQ:DVAX), Novavax (NASDAQ:NVAX), AstraZeneca (NASDAQ:AZN) (+1%).
https://seekingalpha.com/news/3633509-pfizer-biontech-covidminus-19-vaccine-90-effective-u-s-eua-application-expected-this-month
Monday, November 9, 2020
Pfizer/BioNTech COVID-19 vaccine 90% effective, U.S. EUA application seen this month
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.